iX Biopharma disposes of Australian lab testing business for $12 mil after 2Q losses

iX Biopharma disposes of Australian lab testing business for $12 mil after 2Q losses

By: 
Michelle Zhu
18/02/19, 07:59 am

SINGAPORE (Feb 18): iX Biopharma is selling Chemical Analysis, its laboratory testing business in Australia, to Eurofins Australia New Zealand Holding for A$12.5 million ($12 million).  

The consideration is about $10.6 million and $10.84 million over the book value and its net tangible asset value (NTA) of the sale shares, and translates to a net gain on disposal of about $10.4 million.

This comes after the group saw its 2Q losses widen 11% to $3.6 million after registering lower revenue from its chemical analysis division, from which iX Biopharma prioritised and allocated substantial resources to prepare for the nationwide launch of its Entity product range in 4Q19.

In a Monday filing, iX Biopharma says it believes the disposal, which is made on a value-optimised basis, will be in the interest of its shareholders as it expects intensifying competition within Australia’s chemical analysis and testing sector within the next 12 months.

The way the group sees it, opportunities for further development of Chemical Analysis are limited, while maintaining the company’s competitive position and continued growth will require additional capital investments and human resources.

With the sale of Chemical Analysis, the group intends to focus its attention and financial resources to manage its core business – which is the development and commercialisation of innovative therapies to address areas of unmet health needs, and not the non-core, ancillary business of laboratory testing.

The sale is also especially in light of the strides made by iX Biopharma in progressing its pharmaceutical and nutraceutical businesses in the past year, adds the group.

Shares in iX Biopharma closed 1 cent lower at 21 cents on Friday. 

Right timing: STI’s upclimb supported by momentum and moving averages

SINGAPORE (Apr 20): There has been little change in the trend and chart pattern of the Straits Times Index. The index has been on a very glacial ascent towards 3,420, the target indicated when the index broke out of resistance at 3,190 in mid-Jan. Quarterly momentum eased during the past four trading sessions. The 100- and 200-day moving averages have turned positive. This coupled with positively placed DIs and rising ADX should continue to underpin the STI. The only cautionary signals are the somewhat overbought levels of short term stochastics and 21-day RSI, and stagnant vol....
Read More >>

SMI takes legal action against Hyflux; Maybank moves on Tuaspring

(Apr 20): SM Investments (SMI) has terminated its rescue agreement with Hyflux, it announced on Friday. Hyflux, on its part, had already on April 4 terminated the same agreement with SMI. SMI claims it has thus far abided by the agreement. “To clarify, SMI does not accept the purported termination of the Restructuring Agreement by Hyflux on 4 April 2019. This is because the termination was not in accordance with the terms of the Restructuring Agreement," said SMI. Under the agreement reached last October, SMI, led by Indonesian tycoon Anthoni Salim, was to have invested $530 million in....
Read More >>

CCT reports 3.8% higher 1Q DPU of 2.20 cents on higher property contributions

SINGAPORE (April 19): The manager of CapitaLand Commercial Trust (CCT) has reported a 1Q19 distribution per unit (DPU) of 2.20 cents, rising 3.8% y-o-y from 2.12 cents due to higher contributions from Gallileo and Asia Square Tower 2. Gross revenue and net property income (NPI) for the quarter increased by 3.5% and 3.4% to $99.8 million and $79.8 million, respectively. This comes after booking contributions from Gallileo – an office building in Frankfurt, Germany which the trust acquired a 94.9% stake in during June 2018 – as well as higher occupancy at Asia Square Tower 2, both of w....
Read More >>